Navigation Links
Scientists to investigate preventing life-threatening complications in transplant patients
Date:8/20/2012

Scientists from the University of Southampton have received a grant from the blood cancer charity Leukaemia & Lymphoma Research to explore ways of preventing life-threatening side effects in patients receiving bone marrow transplants.

The team, led by Aymen Al-Shamkhani a Professor of Immunology, has received 270,000 for the three-year project to improve transplants, which often offer a last chance of a cure for patients with many different types of blood cancer.

When transplanted, donor bone marrow helps to replenish a healthy blood supply, repairing damage caused by chemotherapy. Among the blood cells transplanted are T-cells, white blood cells crucial to the body's immune system that recognise alien cells and fight infection. In a process called graft-vs-leukaemia (GVL), these new T-cells hunt down any malignant leukaemia cells that have survived chemotherapy.

However, in many cases when the donor and patient are not an exact genetic match, donor T-cells also recognise healthy cells as 'foreign'. The new immune system fights the patient's body in a complication called graft-vs-host disease (GVHD). This occurs in around half of all bone marrow transplants and can be life-threatening and cause long-term health problems.

One way to reduce the chances of developing GVHD is to remove T-cells from the donor bone marrow at the time of the transplant and providing them a later transfusion.

However, delaying the introduction of T-cells reduces the vital GVL effect, creating a high risk of the blood cancer relapsing.

Prof Al-Shamkhani's team will address these problems by investigating ways to stimulate donor T-cells so that they only target the cancerous cells and don't get worn out, thus making the T-cells more effective at fighting the cancer while reducing the chances of GVHD.

Prof Al-Shamkhani said: "Recent research has provided some indication of ways in which GVHD can be prevented, although often the delayed introduction of the T-cells has led to relapse. By gaining a better understanding of the mechanisms of the disease and the way T-cells fight blood cancer, we hope to be able to design treatments that can deliver the best possible chances of survival."

Professor Chris Bunce, Research Director at Leukaemia & Lymphoma Research, said: "GVHD in blood cancer transplants is a major side-effect and often leads to serious health problems, even if the original disease had been destroyed. The potential benefits of this project could go beyond blood cancers, as GVHD can occur in many transplants."


'/>"/>
Contact: Becky Attwood
r.attwood@soton.ac.uk
44-023-805-95457
University of Southampton
Source:Eurekalert

Related medicine news :

1. Scientists solving the mystery of human consciousness
2. Scientists uncover multiple faces of deadly breast cancer
3. Scientists identify major source of cells defense against oxidative stress
4. Scientists tailor cell surface targeting system to hit organelle ZIP codes
5. Scientists rewrite rulebook on breast cancer in landmark global study
6. Warwick scientists uncover how checkpoint proteins bind chromosomes
7. NIH scientists link quickly spreading gene to Asian MRSA epidemic
8. Joslin scientists identify important mechanism that affects the aging process
9. Scripps Research scientists show how memory B cells stay in class to fight different infections
10. Scientists Map Melanomas Genome
11. A*STAR scientists discover switch to boost anti-viral response to fight infectious diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
Breaking Medicine Technology: